A group of scientists belonging to the Centro de Edafología y Biología Aplicada del Segura (CEBAS) in Murcia and the Instituto de Investigaciones Químicas (IIQ) in Seville has been responsible for confirming the effectiveness of new molecules derived from resveratrol applied in very low doses.
The applications patented by the team led by the scientist Juan Carlos Morales Sánchez are aimed at alleviating the effects of intestinal inflammations such as ulcerative colitis, qualities that are added to the already known benefits of resveratrol – produced, among other foods, by grapes – such as its cardioprotective, anticarcinogenic and anti-aging activity.
While previous research on the subject had attested to the benefits of resveratrol at the lowest dose ever tested so far, now the finding has drastically improved the effectiveness of phytoalexin at the same dose.
The prestigious American Journal of Medicinal Chemistry, published by the American Chemical Society, has accepted the study for publication.
Read the interview with Juan Carlos Morales Sánchez.